We have two strong headlines in the marijuana news today; one being Aurora Cannabis Inc (NYSE:ACB) not missing a beat since 2018 with another acquisition, and the other being an increase in funding for marijuana research pouring in post-legalization.
Let’s start with the softer news and then get to the Aurora acquisition.
Obviously, marijuana research was not a priority for governments or businesses when it was still an illegal substance.
That has, by and large, changed since it was legalized, with millions of dollars pouring into research from both the private and public sectors.
In Canada, companies like Canopy Growth Corp (NYSE:CGC) are spending healthy doses of cash to find better ways to cultivate and develop more profitable marijuana strains. (Source: “Legalization sparks boom in once-stigmatized field of marijuana research,” CTV News, January 14, 2019.)
From the government side of things, you have provinces across Canada contributing money to marijuana research at a much higher clip than we’re used to.
All this has served to create a much friendlier environment toward marijuana, and one that could lead to breakthroughs as time goes on.
After all, the company that can develop the most novel and innovative marijuana growing techniques is going to have a natural competitive advantage over its rivals—not to mention that Canadian marijuana stocks, by virtue of their value, will likely have a leg up on the competition due to the free flow of capital.
This will mean that Canada could lead the marijuana industry for decades to come, and makes those Canadian marijuana stocks more desirable than ever.
It is worth noting, however, that Canada isn’t alone in its marijuana research.
If you’ve been keeping up to date with our “Marijuana News Today” columns, you’ll know that Tilray Inc (NASDAQ:TLRY) received